Pharmacotherapy of social anxiety disorder

Bibliography

• Kessler RC, Berglund P, Demler O, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602
   PubMed Web of Science ®Google Scholar
• Grant BF, Hasin DS, Blanco C, The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry 2005;66(11):1351-61
   PubMed Web of Science ®Google Scholar
• Katzelnick DJ, Kobak KA, DeLeire T, Impact of generalized social anxiety disorder in managed care. Am J Psychiatry 2001;158(12):1999-2007
   PubMed Web of Science ®Google Scholar
• Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N. Anxiety disorders and suicidality in the National Comorbidity Survey-Replication. J Psychiatr Res 2009;43(9):825-9
   PubMedGoogle Scholar
• Olfson M, Guardino M, Struening E, Barriers to the treatment of social anxiety. Am J Psychiatry 2000;157(4):521-7
   PubMedGoogle Scholar
• Connor KM, Davidson JR, Chung H, Multidimensional effects of sertraline in social anxiety disorder. Depress Anxiety 2006;23(1):6-10
   PubMedGoogle Scholar
• Schultz LT, Heimberg RG. Attentional focus in social anxiety disorder: potential for interactive processes. Clin Psychol Rev 2008;28(7):1206-21
   PubMedGoogle Scholar
• Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 1998;155(5):613-19
   PubMed Web of Science ®Google Scholar
• Kendler KS, Neale MC, Kessler RC, The genetic epidemiology of phobias in women. The interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia. Arch Gen Psychiatry 1992;49(4):273-81
   PubMedGoogle Scholar
• Rapee RM, Spence SH. The etiology of social phobia: empirical evidence and an initial model. Clin Psychol Rev 2004;24(7):737-67
   PubMedGoogle Scholar
• Stein MB, Goldin PR, Sareen J, Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 2002;59(11):1027-34
   PubMedGoogle Scholar
• Lissek S, Levenson J, Biggs AL, Elevated fear conditioning to socially relevant unconditioned stimuli in social anxiety disorder. Am J Psychiatry 2008;165(1):124-32
   PubMedGoogle Scholar
• Argyropoulos SV, Hood SD, Nutt DJ. Social phobia: illness or illusion? Acta Psychiatr Scand 2001;103(4):241-3
   PubMedGoogle Scholar
• Cornwell BR, Johnson L, Berardi L, Grillon C. Anticipation of public speaking in virtual reality reveals a relationship between trait social anxiety and startle reactivity. Biol Psychiatry 2006;59(7):664-6
   PubMed Web of Science ®Google Scholar
• Hoge EA, Pollack MH, Kaufman RE, Oxytocin levels in social anxiety disorder. CNS Neurosci Ther 2008;14(3):165-70
   PubMedGoogle Scholar
• Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia. Review of a neglected anxiety disorder. Arch Gen Psychiatry 1985;42(7):729-36
   PubMed Web of Science ®Google Scholar
• Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73
   PubMedGoogle Scholar
• Zaider TI, Heimberg RG, Fresco DM, Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med 2003;33(4):611-22
   PubMedGoogle Scholar
• Oosterbaan DB, van Balkom AJ, Spinhoven P, van Dyck R. The placebo response in social phobia. J Psychopharmacol 2001;15(3):199-203
   PubMedGoogle Scholar
• Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 2008;8(2):235-57
   PubMedGoogle Scholar
• Hedges DW, Brown BL, Shwalb DA, The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2007;21(1):102-11
   PubMedGoogle Scholar
• Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002;22(3):257-62
   PubMedGoogle Scholar
• Clark DM, Ehlers A, McManus F, Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71(6):1058-67
   PubMedGoogle Scholar
• Stein MB, Pollack MH, Bystritsky A, Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005;177(3):280-8
   PubMedGoogle Scholar
• Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19(4):241-8
   PubMedGoogle Scholar
• Liebowitz MR, Stein MB, Tancer M, A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002;63(1):66-74
   PubMedGoogle Scholar
• Simon NM, Worthington JJ, Moshier SJ, Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr 2010;15(7):367-73
   PubMedGoogle Scholar
• Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemiol Ment Health 2006;2:35
   PubMedGoogle Scholar
• Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999;14(4):239-45
   PubMedGoogle Scholar
• Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum psychopharmacol 2009;24(4):269-75
   PubMedGoogle Scholar
• Stein DJ, Stein MB, Pitts CD, Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002;63(2):152-5
   PubMedGoogle Scholar
• Montgomery SA, Nil R, Durr-Pal N, A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005;66(10):1270-8
   PubMedGoogle Scholar
• Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002;59(12):1111-18
   PubMedGoogle Scholar
• Walker JR, Van Ameringen MA, Swinson R, Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000;20(6):636-44
   PubMedGoogle Scholar
• Liebowitz MR, Schneier F, Campeas R, Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49(4):290-300
   PubMed Web of Science ®Google Scholar
• Nardi AE, Lopes FL, Valenca AM, Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res 2010;175(3):260-5
   PubMedGoogle Scholar
• Versiani M, Nardi AE, Mundim FD, The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 1996;11(Suppl 3):83-8
   PubMedGoogle Scholar
• Muehlbacher M, Nickel MK, Nickel C, Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005;25(6):580-3
   PubMedGoogle Scholar
• Van Ameringen M, Mancini C, Oakman J, Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry 2007;68(2):288-95
   PubMedGoogle Scholar
• Emmanuel NP, Brawman-Mintzer O, Morton WA, Bupropion-SR in treatment of social phobia. Depress Anxiety 2000;12(2):111-13
   PubMedGoogle Scholar
• Simpson HB, Schneier FR, Campeas RB, Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998;18(2):132-5
   PubMedGoogle Scholar
• Vasile RG, Bruce SE, Goisman RM, Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 2005;22(2):59-67
   PubMedGoogle Scholar
• Davidson JR, Potts N, Richichi E, Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13(6):423-8
   PubMedGoogle Scholar
• Otto MW, Pollack MH, Gould RA, A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 2000;14(4):345-58
   PubMedGoogle Scholar
• Gelernter CS, Uhde TW, Cimbolic P, Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48(10):938-45
   PubMedGoogle Scholar
• Connor KM, Davidson JR, Potts NL, Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998;18(5):373-8
   PubMedGoogle Scholar
• Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004;65(2):244-8
   PubMedGoogle Scholar
• Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994;62(2):350-8
   PubMed Web of Science ®Google Scholar
• Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158(10):1725-7
   PubMedGoogle Scholar
• Pande AC, Davidson JR, Jefferson JW, Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19(4):341-8
   PubMedGoogle Scholar
• Pande AC, Feltner DE, Jefferson JW, Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24(2):141-9
   PubMedGoogle Scholar
• Barnett SD, Kramer ML, Casat CD, Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002;16(4):365-8
   PubMedGoogle Scholar
• Vaishnavi S, Alamy S, Zhang W, Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(7):1464-9
   PubMedGoogle Scholar
• Donahue CB, Kushner MG, Thuras PD, Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. J Anxiety Disord 2009;23(3):362-8
   PubMed Web of Science ®Google Scholar
• Scahill L, Leckman JF, Schultz RT, A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60(7):1130-5
   PubMedGoogle Scholar
• Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991;148(5):598-605
   PubMedGoogle Scholar
• van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997;58(4):164-8
   PubMedGoogle Scholar
• Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009;29(6):561-4
   PubMedGoogle Scholar
• Tauscher J, Kielbasa W, Iyengar S, Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol 2010;20(2):80-7
   PubMedGoogle Scholar
• Stein MB, Ravindran LN, Simon NM, Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry 2010;71(5):627-31
   PubMedGoogle Scholar
• Van Ameringen M, Mancini C, Pipe B, An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004;65(12):1674-8
   PubMedGoogle Scholar
• Dunlop BW, Papp L, Garlow SJ, Tiagabine for social anxiety disorder. Hum Psychopharmacol 2007;22(4):241-4
   PubMedGoogle Scholar
• Kinrys G, Pollack MH, Simon NM, Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003;18(3):169-72
   PubMedGoogle Scholar
• Schneier FR, Blanco C, Campeas R, Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety 2003;17(4):191-6
   PubMedGoogle Scholar
• Connor KM, Cook JL, Davidson JR. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. J Clin Psychiatry 2006;67(1):30-6
   PubMedGoogle Scholar
• Book SW, Thomas SE, Randall PK, Randall CL. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord 2008;22(2):310-18
   PubMedGoogle Scholar
• Adler LA, Liebowitz M, Kronenberger W, Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009;26(3):212-21
   PubMedGoogle Scholar
• Birmaher B, Axelson DA, Monk K, Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003;42(4):415-23
   PubMedGoogle Scholar
• Walkup JT, Albano AM, Piacentini J, Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008;359(26):2753-66
   PubMedGoogle Scholar
• Heimberg RG, Liebowitz MR, Hope DA, Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55(12):1133-41
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Heimberg RG, Schneier FR, Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999;10(3):89-98
   PubMedGoogle Scholar
• Blanco C, Heimberg RG, Schneier FR, A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010;67(3):286-95
   PubMedGoogle Scholar
• Davidson JR, Foa EB, Huppert JD, Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61(10):1005-13
   PubMedGoogle Scholar
• Blomhoff S, Haug TT, Hellstrom K, Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30
   PubMed Web of Science ®Google Scholar
• Haug TT, Blomhoff S, Hellstrom K, Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 2003;182:312-18
   PubMed Web of Science ®Google Scholar
• Knijnik DZ, Blanco C, Salum GA, A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry 2008;23(8):567-74
   PubMedGoogle Scholar
• Hofmann SG, Meuret AE, Smits JA, Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006;63(3):298-304
   PubMedGoogle Scholar
• Guastella AJ, Richardson R, Lovibond PF, A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008;63(6):544-9
   PubMedGoogle Scholar
• Guastella AJ, Howard AL, Dadds MR, A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009;34(6):917-23
   PubMedGoogle Scholar
• Lane C. Shyness; how normal behavior became a sickness. Yale University Press, New Haven, CT; 2007
   Google Scholar